Company / SG&A Expense
NeoGenomics Laboratories, Inc. SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$273.3M
FY2025
5-year range
$221.3M / $273.3M
FY2021-FY2025
Trend
+5.2%
vs FY2024
Sector context
#92 of 158
Health Care
What the data says
At $273M, NeoGenomics Laboratories, Inc.'s sg&a expense ranks #67 of 158 in the Health Care sector. Increased from $243M to $273M over the past 2 years.
Based on SEC 10-K filings.
$273M in FY2025 with a 5-year CAGR of +13.7%.
Increased from $243M to $273M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +3.9%
- 5-Year CAGR
- +13.7%
- 10-Year CAGR
- -
Sector benchmark
#67 of 158 in Health CareTop 42% of 158This company $273.3M Sector average $175.9B
▼
-99.8% below sector average
Key checks
Key Insights
- 5-year CAGR of +13.7%, indicating consistent growth.
- In FY2025, sg&a expense increased 5.2% year-over-year.
- Ranks #92 out of 158 companies in the Health Care sector.
- Lowest sg&a expense in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score 0.56 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $273.3M | +5.2% |
| FY2024 | $259.7M | +6.8% |
| FY2023 | $243.1M | -0.1% |
| FY2022 | $243.4M | +9.9% |
| FY2021 | $221.3M | +53.9% |
| FY2020 | $143.8M | +12.3% |
| FY2019 | $128.0M | +50.9% |
| FY2018 | $84.8M | +20.6% |
| FY2017 | $70.4M | +10.1% |
| FY2016 | $63.9M | +90.1% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026